Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney

Yu-lan AN; Chang-xia CAO; Yu-mei TIAN; Lei REN; Zhi-fang LI; Rong CHENG; Hai-ping LI; Tao WU; Bao-ming TANG

doi:10.13422/j.cnki.syfjx.20202429

您当前的位置：

首页 >

文章列表页 >

Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney

Clinic | 更新时间：2021-03-05

- Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 6, Pages: 69-75(2021)
- 作者机构：
  
  青海大学附属医院，西宁 810001
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20202429
  CLC： R22;R242;R2-031;R287
- Received：17 September 2020，
  
  Published Online：13 October 2020，
  
  Published：20 March 2021
- 稿件说明：
移动端阅览
安玉兰,曹昌霞,田玉梅等.金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症的疗效及对免疫炎症因子的调节作用[J].中国实验方剂学杂志,2021,27(06):69-75.

AN Yu-lan,CAO Chang-xia,TIAN Yu-mei,et al.Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(06):69-75.
安玉兰,曹昌霞,田玉梅等.金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症的疗效及对免疫炎症因子的调节作用[J].中国实验方剂学杂志,2021,27(06):69-75. DOI： 10.13422/j.cnki.syfjx.20202429.

AN Yu-lan,CAO Chang-xia,TIAN Yu-mei,et al.Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(06):69-75. DOI： 10.13422/j.cnki.syfjx.20202429.

摘要

目的

观察金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症（PMO）脾肾两虚证的临床疗效，对细胞免疫炎症因子的调节作用。

方法

将160例患者按随机数字表分为对照组和观察组，每组80例。两组患者均给予综合西医治疗措施，对照组口服壮骨止痛胶囊，4粒/次，3次/d；观察组口服金匮肾气丸联合补中益气汤治疗，1剂/d。两组均连续治疗24周。采用双能Ｘ射线吸收检测法（DXA）测量治疗前后腰椎L

2-4

骨密度和定量CT（QCT）测量治疗前后腰椎骨密度；进行中医证候评分和中国人骨质疏松症生存质量简明量表（COQOL）评分；检测治疗前后雌二醇（E

），Ⅰ型原胶原氨基端前肽（PINP），血清骨钙素（OC），骨保护素（OPG），Ⅰ型胶原交联C末端肽（S-CTX），抗酒石酸酸性磷酸酶（TRACP）和尿吡啶啉（PYD）水平；检测治疗前后CD4

T细胞，CD8

T细胞，白细胞介素-17（IL-17），肿瘤坏死因子-

（TNF-

），

γ-

干扰素（IFN-

）和白细胞介素-4（IL-4）水平，计算CD4

T细胞中辅助性T细胞（Th）17和调节性T细胞（Treg）的比例；进行安全性评价。

结果

观察组DXA测量骨密度，T和QCT测量骨密度均高于对照组（

0.01）；观察组中医证候评分和COQOL评分均低于对照组（

0.01）；观察组PINP，OC，S-CTX，TRACP和PYD/Cr水平均低于对照组，OPG高于对照组（

0.01）；观察组CD8

和Treg水平高于对照组（

0.05），Th17，Th17/Treg，CD4

/CD8

低于对照组（

0.05）；观察组IL-17，TNF-

，IFN-

水平低于对照组，IL-4和E

水平高于对照组（

0.01）；观察组疗效优于对照组（

2.103，

0.05）。

结论

采用金匮肾气丸联合补中益气汤治疗PMO脾肾两虚型患者，可提高E

水平，提高骨密度，减轻临床症状，提高生活质量，能调节骨代谢指标和免疫炎症反应，有着较好的临床疗效，且安全。

Abstract

Objective

To observe the clinical efficacy of addition and subtraction therapy of Jinkui Shenqiwan combined with Buzhong Yiqitang to postmenopausal osteoporosis （PMO） with deficiency of spleen and kidney， and to investigate its regulation effect on immune inflammatory factors.

Method

One hundred and sixty patients were randomly divided into observation group and control group， with 80 cases in each group. Both groups got comprehensive western medicine treatment measures. Patients in control group additionally got Zhuanggu Zhitong capsule， 4 capsules/time， 3 times/day. Patients in observation group additionally got addition and subtraction therapy of Jinkui Shenqiwan combined with Buzhong Yiqitang， 1 dose/day. The treatment was continued for 24 weeks. Before and after treatment， lumbar L2-4 bone mineral density （BMD） was detected by Dual energy X-ray absorptiometry （DXA） and lumbar BMD was detected by quantitative CT （QCT）. Scores of traditional Chinese medicine（TCM） syndromes and Chinese osteoporosis-targeted quality of life questionnaire （COQOL） were graded. Levels of Estradiol （E

）， type Ⅰ procollagen amino terminal pro peptide （PINP）， serum osteocalcin （OC）， osteoprotegerin （OPG）， type Ⅰ collagen cross-linked C-terminal peptide （S-CTX）， tartrate resistant acid phosphatase （TRACP） and urinary pyridinoline （PYD） were detected. Levels of CD4

T cells， CD8

T cells， interleukin-17 （IL-17）， tumor necrosis factor-

（TNF-

），

γ-

interferon（IFN-

） and interleukin-4 （IL-4） were calculated. The proportion of T helper cell （Th）17 and regulatory T cell （Treg） in CD4

T cells was calculated. Besides， the safety was evaluated.

Result

Bone density was detected by DXA in observation group， and its T-value and bone density detected by QCT were all higher than those in control group （

0.01）. After treatment， scores of TCM syndrome and COQOL were lower than those in control group （

0.01）. Levels of PINP， OC， S-CTX， TRACP and PYD/Cr were all lower than those in control group （

0.01）. Levels of OPG， CD8

and Treg were higher than those in control group （

0.05）， levels of Th17， Th17/Treg， CD4

/CD8

， IL-17， TNF-

and IFN-

were lower （

0.01）， and levels of IL-4 and E

were higher than those in control group （

0.01）. The clinical efficacy in observation group was better than that in control group （

=2.103，

0.05）.

Conclusion

On the basis of calcium and vitamin D supplementation， Jinkui Shenqiwan combined with Buzhong Yiqitang can improve levels of E

and bone density， reduce clinical symptoms， improve quality of life， regulate bone metabolism index and immune inflammation reaction， with better clinical efficacy and safety.

关键词

Keywords

references

中华医学会骨质疏松和骨矿盐疾病分会 . 原发性骨质疏松症诊疗指南（2017）［J］. 中华骨质疏松和骨矿盐疾病杂志， 2017 ， 10 （ 5 ）： 413 - 443 .

潘心瑶，谢欣薇，周琦，等 . 绝经后骨质疏松症中医药研究进展［J］. 中国中西医结合杂志， 2019 ， 39 （ 9 ）： 1140 - 1147 .

中华中医药学会 . 绝经后骨质疏松症（骨痿）中医药诊疗指南（2019年版）［J］. 中医正骨， 2020 ， 32 （ 2 ）： 1 - 13 .

仇宋明，尹恒，王建伟 . 基于“脾肾相关”论治疗骨质疏松症的研究进展［J］. 中国骨质疏松杂志， 2019 ， 25 （ 12 ）： 1809 - 1811，1816 .

徐绍俊，黄建烽，邵敏，等 . 补肾方剂对绝经后骨质疏松症大鼠的影响及其作用机制研究［J］. 中药新药与临床药理， 2017 ， 28 （ 5 ）： 588 - 593 .

王建伟，马勇，张亚峰，等 . 金匮肾气丸联用葡萄糖酸钙治疗原发性骨质疏松症的临床研究［J］. 中国骨质疏松杂志， 2011 ， 17 （ 10 ）： 912 - 914，911 .

马清华，张竞 . 补中益气汤加减对老年性骨质疏松（脾肾两虚证）的临床疗效分析［J］. 中医药临床杂志， 2017 ， 29 （ 4 ）： 551 - 553 .

许莹萍，邱学敏，桂玉燕，等 . CD4 + T细胞在绝经后骨质疏松症发病机制中的调控作用［J］. 中国免疫学杂志， 2016 ， 32 （ 4 ）： 584 - 587 .

国家食品药品监督管理局药品评审中心 . 中药新药治疗原发性骨质疏松症临床研究技术指导原则［M］. 北京：中国医药科技出版社， 2015 ： 95 - 102 .

何藻鹏，杨德鸿，李丽 . 中国人骨质疏松症生存质量简明量表的编制与信效度［J］. 南方医科大学学报， 2014 ， 34 （ 11 ）： 1637 - 1641 .

张紫嫣，黄雅薇，张新雪，等 . 中医“肾髓系统”的初步构建［J］. 世界科学技术—中医药现代化， 2017 ， 19 （ 5 ）： 749 - 752 .

侯文芳，肖文华，洪天配 . 骨质疏松症相关标志物实验室检查的发展与展望［J］. 中华检验医学杂志， 2017 ， 40 （ 11 ）： 835 - 838 .

SINGH S ， KUMAR D ， LAL A K . Serum osteocalcin as a diagnostic biomarker for primary osteoporosis in women ［J］. J Clin Diagn Res ， 2015 ， 9 （ 8 ）： RC04-RC07 .

MOLDOVAN D ， RUSU C ， POTRA A ， et al . Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients ［J］. Int Urol Nephrol ， 2017 ， 49 （ 5 ）： 895 - 901 .

PASCHALIS E P ， GAMSJAEGER S ， HASSLER N ， et al . Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality ［J］. Bone ， 2017 ， 95 ： 41 - 46 .

徐玉善，江艳，李少遊，等 . 绝经后骨质疏松症的T细胞亚群的变化及意义［J］. 昆明医科大学学报， 2015 ， 36 （ 4 ）： 34 - 36 .

DAR HY ， PAL S ， SHUKLA P ， et al . Bacillus clausii inhibits bone loss by skewing Treg-Th17 cell equilibrium in postmenopausal osteoporotic mice model ［J］. Nutrition ， 2018 ， 54 ： 118 ‐ 128 .

LI J Y ， CHASSAING B ， TYAGI A M ， et al . Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics ［J］. J Clin Invest ， 2016 ， 126 （ 6 ）： 2049 ‐ 2063 .

WANG L ， LIU S ， ZHAO Y ， et al . Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass ［J］. Cell Death Differ ， 2015 ， 22 （ 10 ）： 1654 ‐ 1664 .

BODEGRAVEN A V A ， BRAVENBOER N . Perspective on skeletal health in inflammatory bowel disease ［J］. Osteoporos Int ， 2020 ， 31 （ 4 ）： 637 ‐ 646 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Regulatory Effect of Guilu Bugu Prescription in Treating Th17/ Treg Cell Factors of Patients with Postmenopausal Osteoporosis Based on Syndrome Differentiation

Characteristics of Traditional Chinese Medicine Syndromes in Patients with Concurrent Postmenopausal Osteoporosis and Knee Osteoarthritis

Buzhong Yiqitang Regulates Mitochondrial Homeostasis of Skeletal Muscle via PINK1 Pathways to Resist Exercise-induced Fatigue

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Induces Ferroptosis by Regulating PCBP1 to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer

Related Author

Jin-yong LIU

He-ming WANG

Jian LIN

Xiu-ming CHEN

Yue-long FANG

Xiao-wen LIAN

Shu-he CAI

CUI Xin

Related Institution

Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine

Fujian Key Laboratory of Rehabilitation Technology

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Beijing Electric Power Hospital of State Grid Corporation of China

Wangjing Hospital， China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰